Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Humanetics Reports Positive Phase 2 Clinical Trial Results in COVID-19 Study
Details : BIO 300 (genistein) is a DNA topoisomera II inhibitor administered as an oral suspension. It is being investigated for COVID-19 infection.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2025
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Department of Defense
Deal Size : Undisclosed
Deal Type : Funding
Humanetics Secures Funding for Drug to Prevent Radiation Injury Development
Details : The Company aims to develop its drug, BIO 300, as a medical countermeasure to reduce bodily harm caused by acute exposure to radiation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Department of Defense
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Genistein
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Greenstone Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Genistein
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Greenstone Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : US Department of Defense
Deal Size : $3.0 million
Deal Type : Funding
Uniformed Services University Grants Support for Humanetics Radiation Countermeasure
Details : The Funding will be used to advance the company's lead product BIO 300 (genistein), which is being evaluated in the early-stage clinical trial studies for the treatment of Acute Radiation Syndrome.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 08, 2024
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : US Department of Defense
Deal Size : $3.0 million
Deal Type : Funding
Lead Product(s) : Genistein
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Greenstone Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiovascular Genistein Therapy for Heart Failure Inflammation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2024
Lead Product(s) : Genistein
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Greenstone Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Genistein
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : National Heart, Lung, And Blood Institute
Deal Size : Undisclosed
Deal Type : Funding
Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis
Details : The funding will support a series of studies with its new drug candidate, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a treatment for idiopathic pulmonary fibrosis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Genistein
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : National Heart, Lung, And Blood Institute
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Department of Defense
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to develop Humanetics' drug, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 09, 2023
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Department of Defense
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BIO 300 (genistein) is a small molecule drug candidate which increases the killing effect of radiation on multiple tumor thus selectively protect normal tissues and to avoid protection of tumor cells. It is being developed as a treatment of inflammatory ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2023
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder
Details : BIO 300 (Genistein) Oral Powder is the Company’s medical countermeasure under development to prevent acute radiation syndrome (ARS). The article details results from the trial including safety, pharmacokinetics, and biomarkers in 34 healthy volunteers.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2022
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting
Details : BIO 300 Oral Powder (Genistein) is a new formulation that was developed to address unique operational needs of military personnel and first responders. It is a solid oral dosage formulation that is shelf-stable and can be self-administered.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2022
Lead Product(s) : Genistein
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable